Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted an...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/920361 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524794543046656 |
|---|---|
| author | Ali Zalpour Thein Hlaing Oo |
| author_facet | Ali Zalpour Thein Hlaing Oo |
| author_sort | Ali Zalpour |
| collection | DOAJ |
| description | Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Two pharmacologically distinct classes of targeted agents are dabigatran etexilate (Direct Thrombin Inhibitor (DTI)) and rivaroxaban, apixaban, and edoxaban (direct oral factor Xa inhibitors (OFXaIs)). Emerging evidence from the clinical trials has shown that DOACs are noninferior to VKA or low-molecular-weight heparins in the prevention and treatment of thromboembolism. This review examines the role of edoxaban, a recently approved OFXaI, in the prevention and treatment of thromboembolism based on the available published literature. The management of edoxaban in the perioperative setting, reversibility in bleeding cases, its role in cancer patients, the relevance of drug-drug interactions, patient satisfaction, financial impacts, and patient education will be discussed. |
| format | Article |
| id | doaj-art-9da8c121b15242e193c5ea10d4fa4463 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-9da8c121b15242e193c5ea10d4fa44632025-02-03T05:47:21ZengWileyAdvances in Hematology1687-91041687-91122015-01-01201510.1155/2015/920361920361Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceAli Zalpour0Thein Hlaing Oo1University of Texas MD Anderson Cancer Center, 1400 Pressler Avenue, Unit 1465, FCT 13.5021, Houston, TX 77030, USASection of Thrombosis & Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAVitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Two pharmacologically distinct classes of targeted agents are dabigatran etexilate (Direct Thrombin Inhibitor (DTI)) and rivaroxaban, apixaban, and edoxaban (direct oral factor Xa inhibitors (OFXaIs)). Emerging evidence from the clinical trials has shown that DOACs are noninferior to VKA or low-molecular-weight heparins in the prevention and treatment of thromboembolism. This review examines the role of edoxaban, a recently approved OFXaI, in the prevention and treatment of thromboembolism based on the available published literature. The management of edoxaban in the perioperative setting, reversibility in bleeding cases, its role in cancer patients, the relevance of drug-drug interactions, patient satisfaction, financial impacts, and patient education will be discussed.http://dx.doi.org/10.1155/2015/920361 |
| spellingShingle | Ali Zalpour Thein Hlaing Oo Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence Advances in Hematology |
| title | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| title_full | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| title_fullStr | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| title_full_unstemmed | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| title_short | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| title_sort | update on edoxaban for the prevention and treatment of thromboembolism clinical applications based on current evidence |
| url | http://dx.doi.org/10.1155/2015/920361 |
| work_keys_str_mv | AT alizalpour updateonedoxabanforthepreventionandtreatmentofthromboembolismclinicalapplicationsbasedoncurrentevidence AT theinhlaingoo updateonedoxabanforthepreventionandtreatmentofthromboembolismclinicalapplicationsbasedoncurrentevidence |